Compare Citigroup Inc. (C) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Citigroup Inc. vs State Street SPDR S&P Biotech ETF — how do they compare? Citigroup Inc. trades at $135.93 (market cap $227.75B), while State Street SPDR S&P Biotech ETF trades at $158.28. The key difference: Citigroup Inc. pays a 1.97% dividend while State Street SPDR S&P Biotech ETF pays none, and State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, Citigroup Inc. nearer its low. Which is the better fit depends on your goals.
| C | XBI | |
|---|---|---|
Market Cap | $227.75B | — |
Sector | Financials | Broad Market / Factor |
52-Week High | $145.67 | $164.28 |
52-Week Low | $92.59 | $86.92 |
Dividend Yield | 1.97% | — |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Citigroup Inc.
Citigroup Inc. is a diversified financial services holding company that provides a broad range of financial services to consumer and corporate customers. The Company services include investment banking, retail brokerage, corporate banking, and cash management products and services. Citigroup serves customers globally.
Read more on C →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
